Spyre Therapeutics (SYRE)
NASDAQ:SYRE
Want to see SYRE full AI Analyst Report?
SYRE Stock Chart & Stats
$73.01
-$0.27(-1.11%)
At close: 4:00 PM EST
$73.01
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$12.29 - $75.00
Previous CloseN/A
Volume84.75K
Average Volume (3M)1.18M
Market Cap
$5.99B
Enterprise Value$4.12B
Total Cash (Recent Filing)$756.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
May 07, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding86,015,170
10 Day Avg. Volume1,927,091
30 Day Avg. Volume1,175,424
Financial Highlights & Ratios
PEG Ratio1.94
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue45.55
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-23.00
Forecast
1Y Price Target
$91.00Price Target Upside24.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Development And Co-fundingA multi‑arm platform design together with a major co‑funding agreement for an IL‑23 plus TNFα co‑antibody increases the likelihood of advancing combination regimens and creating multiple future value catalysts.
Efficacy DifferentiationSPY001 produced high clinical remission and notable endoscopic improvement in the SKYLINE readout, indicating potential to outperform current therapies and support a best‑in‑class positioning.
Exposure-optimized DosingHalf‑life extension and dose optimization for SPY001 led most patients to achieve higher drug exposure versus historical comparators, reinforcing confidence in the selected dosing strategy and expected clinical benefit.
Bears Say
Cash Runway And Dilution RiskA constrained cash runway combined with high cash burn raises the likelihood of additional financing that could dilute shareholders and complicate execution of late‑stage development plans.
Limited Trial EvidenceEfficacy signals were derived from a small open‑label cohort without a control arm, which limits the ability to predict how results will perform in larger randomized trials.
Reliance On Future Placebo-controlled CohortsAnalyst confidence is contingent on additional placebo‑controlled cohorts and further readouts, creating material clinical execution risk if subsequent data fail to confirm early findings.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $12.29 and its highest was $75.00 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $5.99B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 10 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Feb 19, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.709 by $0.009.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.67.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 86,015,170 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.709. Following the earnings report the stock price went up 14.282%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.00 (24.64% Upside)
$91.00 (24.64% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 41.2%
Last 30 Days ▲ 41.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.24%
12-Months-Change
Fundamentals
Return on Equity
-29.44%
Trailing 12-Months
Asset Growth
27.82%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$91.00
▲(24.64% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
6.69% Insiders
23.28% Mutual Funds
0.09% Other Institutional Investors
59.43% Public Companies and Individual Investors
Options Prices
Currently, No data available
---